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Abstract: We present recent advances in the genetics of recurrent vertigo, including familial episodic ataxias, migraneous 
vertigo, bilateral vestibular hypofunction and Meniere’s disease. 
Although several vestibular disorders are more common within families, the genetics of vestibulopathies is largely not 
known. Genetic loci and clinical features of familial episodic ataxias have been defined in linkage disequilibrium studies 
with mutations in neuronal genes KCNA1 and CACNA1A. Migrainous vertigo is a clinical disorder with a high comor-
bidity within families much more common in females with overlapping features with episodic ataxia and migraine. Bilat-
eral vestibular hypofunction is a heterogeneous clinical group defined by episodes of vertigo leading to progressive loss of 
vestibular function which also can include migraine. Meniere’s disease is a clinical syndrome characterized by spontane-
ous episodes of recurrent vertigo, sensorineural hearing loss, tinnitus and aural fullness and familial Meniere’s disease in 
around 10-20% of cases. An international collaborative effort to define the clinical phenotype and recruiting patients with 
migrainous vertigo and Meniere’s disease is ongoing for genome-wide association studies.  
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INTRODUCTION 
  Genomic medicine in complex middle or inner ear dis-
eases such as chronic otitis media, otosclerosis or age-related 
hearing loss is an emerging topic [1]. Patients with imbal-
ance or recurrent vertigo are a heterogeneous group of com-
plex disorders affecting the peripheral and central vestibular 
system and they represent a diagnostic challenge for the cli-
nicians since their genetic basis is largely not known. Famil-
iar episodic ataxias are rare cause of recurrent vertigo, but 
molecular genetics has identified several mutations on 
KCNA1 and CACNA1A genes that suggest a key role for 
voltage-gated channels and solute carriers in the plasma 
membrane of neurons in recurrent vertigo. Moreover, recent 
advances in familiar vestibular disorders and particularly in 
familial Menière’s disease have facilitated the pathways for 
clinical characterization and recruitment of patients for large 
collaborative studies. 
  Recurrent vertigo with vestibular hypofunction is a 
common symptom in clinical practice and there is a heredi-
tary component in neurotologic disorders that is not well 
defined. Migraine has a strong genetic background and it is 
frequently observed in these patients and although the ge-
nomics for migraine has started to become known [2, 3], the 
shared allelic variants between vertigo and migraine remain 
to be discovered. This review will include syndromes with 
recurrent or episodic vertigo: familial episodic ataxia,   
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migrainous vertigo, bilateral vestibular hypofunction and 
Ménière’s disease. 
FAMILIAL EPISODIC ATAXIAS 
  Familial episodic ataxias are monogenic recurrent vertigo 
syndromes. Most of them are autosomal dominant disorders 
of early onset characterized by recurrent attacks of incoordi-
nation, dysarthria and truncal ataxia. There are several sub-
types defined by associated interictal findings and genetic 
characterizations (Table 1). The key clinical feature that 
raises the diagnosis of episodic ataxia is discrete attacks of 
incoordination with a clear onset and resolution of symp-
toms, which also distinguishes episodic ataxia with progres-
sive features from progressive ataxia with intermittent exac-
erbation. The presence of interictal findings in most patients 
provides a helpful distinction with vestibular migraine. 
Episodic Ataxia Type 1 (EA1) 
  EA1 is a potassium channelopathy characterized by con-
stant myokymia and episodes of spastic contractions of mus-
cles of the head, arms and legs. The attacks consist of epi-
sodes of vertigo lasting minutes associated with diplopia, 
headache, stiffness of the body and dysarthric speech. 
  EA1 is caused by mutations in KCNA1 gene located on 
chromosome 12p13 (MIM 160120), which encodes Kv1.1, a 
voltage-gated potassium channel [4]. Functional Kv1.1 
channels are tetrameric structures composed of four identical 
monomers, but K+ channel diversity is greatly enhanced by 
the ability to form heteromeric channels composed of Kv1.1 
and Kv1.2/Kv1.4/KvB1.1. In several brain areas, Kv1.1 co-
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properties to heteromeric channels. It is likely that the rate of 
inactivation will be determined by the number of Kv1.4 
subunits which is increased in EA1 [4], resulting in an in-
crease in neuronal excitability [5, 6]. Individuals with EA1 
are heterozygous for a KCNA1 disease-causing mutation, 
and they have a wild-type and a mutated allele, which may 
be equally expressed; so, channels composed of wild-type 
and mutated subunits may be formed, but this heterozygous 
allele is enough to alter the function of heteromeric channels 
containing Kv1.1 subunits [7, 8]. 
  The KCNA1 gene has a transcript of 7983 nucleotides 
with a coding region of 1488 [7]. To date, more than 20 
KCNA1 mutations have been described and most are mis-
sense mutations distributed throughout the gene [9]. Interest-
ingly, four different mutations of the highly conserved 
threonine 226 in the second transmembrane segment 
(T226M/A/R/K) that lead to diverse phenotype have been 
identified [10]. 
Episodic Ataxia Type 2 (EA2) 
  EA2 is a Ca
2+ channelopathy characterized by recurrent 
vertigo lasting from hours to days, with imbalance, vomiting, 
ataxia with interictal nystagmus (MIM 108500). It is distin-
guished from EA1 by the absence of myokymia (fine rip-
pling of muscles). Episodes are triggered by exercise, an 
intercurrent infection, stress, alcohol and caffeine and they 
are often relieved by treatment with the carbonic anhydrase 
inhibitor, acetazolamide [11]. Migraine occurs in about 50% 
of patients with EA2. 
  EA2 is caused by mutations in the CACNA1A gene, 
mapped to chromosome 19p13 [12], which encodes the -
subunit of the P/Q-type voltage-gated calcium channel, 
Cav2.1 [13, 14]. This gene is widely expressed throughout 
the CNS, showing highest levels at Purkinje and granule 
cells of the cerebellum.  
  Dominant mutations in CACNA1A underlie at least three 
allelic diseases: EA2, familial hemiplegic migraine type 1 
and spinocerebellar ataxia type 6. A large number of differ-
ent single nucleotide mutations have been shown to cause 
EA2 which results in premature stop codons and a non func-
tional protein with loss of Cav2.1 channel function [15, 16], 
including recent mutations in the promoter and a new final 
exon 48 [16]. Moreover, these mutant subunits may disrupt 
the membrane trafficking of wild-type subunits [17]. 
CACNA1A alternative splicing in the cerebellum of selected 
exons harboring nonsense mutations (such as exon 37A) can 
also cause EA2 [18]. Direct sequencing of CACNA1A in 
some patients with EA2 does not identify any point muta-
tion, but the use of methods such as MLPA (multiplex liga-
tion-dependent probe amplification) and QMPSF (quantita-
tive multiplex PCR of short fluorescent fragments) has dem-
onstrated large-scale CACNA1A gene rearrangements (dele-
tions and duplications) in patients with EA2 [19,20]. 
  Familial hemiplegic migraine type 1 is a form of mi-
graine with aura and reversible hemiparesis also caused by 
missense nucleotide mutations in the CACNA1A gene that 
alter channel gating and enhance the channel activity at 
negative potentials [21].  
  Spinocerebellar ataxia type 6 (SCA6) is an autosomal 
dominant disorder characterized by a late onset slowly pro-
gressive ataxia, dysarthria and nystagmus associated with an 
abnormal CAG expansion in exon 47 of CACNA1A gene 
[22]. The normal number of CAG repeats ranges up to 18 
and individuals with SCA6 have 20 to 33 repeats in the car-
boxy-terminal domain, resulting in a polyglutamine expan-
sion of the carboxyl- terminal domain [22]. 
Episodic Ataxia Type 3 (EA3) 
  EA3 (MIM 606554) was described in 26 members of a 
single large Canadian family with episodic vertigo, tinnitus, 
ataxia, migraine and interictal myokimia [23]. Patients re-
spond to acetazolamide and no residual ataxia was observed 
after the episodes. The disease locus for EA3 has been 
mapped to chromosome 1q42 [24]. 
Episodic Ataxia Type 4 (EA4) 
  EA4, also called familial periodic vestibulocerebellar 
ataxia (MIM 606552), is an autosomal dominant disorder 
characterized by episodes of vertigo and ataxia beginning in 
the third to sixth decade of life described in two families of 
North Caroline, USA [25, 26]. Patients may have interictal 
nystagmus and mild ataxia similar to EA2 or they may be 
completely normal in between attacks. The episodes usually 
last for hours and are not relieved by acetazolamide. The 
most consistent symptom is the inability to suppress the ves-
tibulo-ocular reflex. Linkage analysis ruled out the EA1 and 
Table 1.  Genetic and Clinical Summary of Episodic Ataxia Syndromes 
EA Type  Age at onset, y 
Duration of  
episodes 
Associated symptoms  Interictal findings  Gene locus  Gene 
EA1  <20  Minutes  Muscle spams  Myokimia, seizures  12p13  KCNA1 
EA2 <20  Hours  Vertigo,  weakness  Ataxia,  nystagmus  19p13  CACNA1A 
EA3 <20  Minutes  Vertigo,  tinnitus,  headache  No 1q42  Unknown 
EA4  20-50  Hours  Vertigo, diplopia  Nystagmus, abnormal smooth pursuit  Unknown Unknown 
EA5 20-60  Hours  Vertigo  Nystagmus,  ataxia  2q22-23  CACNB4 
EA6  <10  Hours  Cognitive impairment  Seizures, ataxia  5p13  SLC1A3 
EA7 <20  Hours  Vertigo  No  19q13  Unknown Genetics of Recurrent Vertigo and Vestibular Disorders  Current Genomics, 2011, Vol. 12, No. 6    445 
EA2 loci as well as loci for SCA1–5 [27], but the locus has 
not been identified. 
Episodic Ataxia Type 5 (EA5) 
  EA5 (MIM601949) was identified when a series of fami-
lies with episodic ataxia and epilepsy harboured mutations in 
the calcium channel b4 subunit CACNB4, on chromosome 
2q22-23 [28]. The premature-termination mutation R482X 
was identiﬁed in a patient with juvenile myoclonic epilepsy. 
The R482X protein lacks the 38 C-terminal amino acids con-
taining part of an interaction domain for the subunit. The 
missense mutation C104F was discovered both in a German 
family with generalized epilepsy and praxis-induced seizures 
and in a Canadian family with episodic ataxia. These coding 
mutations were not detected in unaffected controls [29]. 
Episodic Ataxia Type 6 (EA6) 
  EA6 (MIM612656) was first identified in a 10-year-old 
child with an episodic and progressive ataxia, seizures, alter-
nating hemiparesis and episodes of migraine [30]. A de-novo 
P290R heterozygous mutation was identified by candidate 
gene approach in SLC1A3 (MIM 600111). This is a solute 
carrier gene which encodes the glial excitatory amino acid 
transporter type 1 (EAAT1), which is involved in glutamate 
removal from the synapses [30]. A second mutation C186S 
was identified in 3 symptomatic members of a family with 
EA, without motor symptoms or seizures, suggesting a rela-
tionship between the phenotype and the extent of glutamate 
transporter dysfunction [31]. 
Episodic Ataxia Type 7 (EA7) 
  EA7 (MIM611907) was described in a family of 7 mem-
bers with vertigo, weakness, dysarthria and ataxia lasting 
from hours to days typically triggered by exercise or excite-
ment, with onset before age 20 [32]. There is no interictal 
finding (which distinguishes it from EA3). Genome scan 
mapped the locus of EA7 between rs1366444 and rs952108 
on chromosome 19q13. 
VESTIBULAR MIGRAINE (VM) 
  Migraine is an episodic headache disorder affecting 8% 
of males and 17% of females [33]. Clinically, the Interna-
tional Classification of Headache Disorders (ICHD-II) [34] 
recognizes two main common forms of migraine: migraine 
with aura and migraine without aura. The two forms are dis-
tinguished from each other based on the presence of aura, a 
period of variable and diverse neurological symptoms that 
precedes the headache phase. There is a dilemma among the 
scientific community whether migraine with aura and mi-
graine without aura attacks represent two different disorders 
or if they are variations of a single disease having a common 
complex genetic background. 
  The clinical criteria required for diagnosing VM are cur-
rent or previous history of migraine according to ICHD-II 
criteria [34] and at least 2 attacks of vertigo presenting with 
1 of the following symptoms: migrainous headache, photo-
phobia, phonophobia, or visual or other auras. Vertigo is not 
considered to be an aura of migraine [35]. VM is found in 1-
3% of the population, being the most common cause of re-
current vertigo. Migraine is a complex polygenic disease and 
this may explain clinical heterogeneity (migraine, aura or 
vertigo).  
  A recent genome-wide association study of 2731 Euro-
pean migraine patients has identified rs1835740 on chromo-
some 8q22.1 (P = 5.38  1 10
9, odds ratio = 1 1.23, 95% CI 
1 1.150–1.324). The association was replicated in 3,202 
cases and 40,062 controls [2]. The rs1835740 is located be-
tween MTDH (astrocyte elevated gene 1, also known as 
AEG-1) and PGCP (encoding plasma glutamate carboxypep-
tidase). In an expression study in lymphoblastoid cell lines, 
transcript levels of the MTDH were found to have a signifi-
cant correlation with rs1835740 minor allele. MTDH down-
regulates SLC1A2, the gene encoding the major glutamate 
transporter (EAAT2) in the brain [36, 37], suggesting that 
the identified variant regulates glutamate in the synapsis. In 
another population-based genome-wide analysis including 
5122 migraineurs and 18108 non-migraineurs individuals, 
rs2651899 (1p36.32, PRDM16) rs10166942 (2q37.1, 
TRPM8) and rs11172113 (12q13.3, LRP1) were among the 
top markers associated with migraine. The meta-analysis of 
three replication cohorts including 774 from Netherlands, 
306 from Germany and 2748 from the International Head-
ache Genetics Consortium confirmed the association when 
discovery and replication cohorts were pooled [3]. TRPM8 
encodes a sensor for cold and cold-induced pain and is a 
target for neuropathic pain [38]. The potential role of 
PRDM16 in migraine is unclear. LRP1 is a member of the 
lipoprotein family which modulates synaptic transmission 
and co-localizes with NMDA receptor in neurons [39], sup-
porting that glutamate homeostasis is relevant in the patho-
physiology of migraine. Future challenges should be a 
GWAS in VM patients, since this is a subtype of migraine 
patients to define endophenotypes and a fine mapping analy-
sis of MTDH, TRPM8 and LRP1 genes in VM. 
Familial Migranous Vertigo/Familial VM 
  In 1994, a set of three families with multiple members 
who experienced migraine and episodes of vertigo lasting 
minutes followed years later by progressive loss of periph-
eral vestibular function was reported [40]. A 4-generation 
family with 23 members with vestibular migraine inherited 
as a dominant trait has been described [41]. Members of this 
family have episodic vertigo and migraine with aura. A ge-
nome-wide screen for loci linked to MV segregating in this 
large family and subsequent fine structure mapping demon-
strated that the disease gene is located between loci rs244895 
and D5S2073 in chromosome 5q35. Candidate genes in this 
region, including KCNMB1 (Kv channel interacting protein 
1 isoform 1), KCNIP1 (potassium large conductance calcium 
activated), ATP6V0E (ATPase, H+ transporting, lysosomal, 
V0 subunit E), SLC34A1 (solute carrier family 34 sodium 
phosphate), GABRP (gamma-amino butyric acid-GABA A 
receptor); DRD1 (dopamine receptor D1); and HRH2 (his-
tamine receptor H2) were sequenced, but no mutation was 
identified [41].  
BILATERAL VESTIBULAR HYPOFUNCTION (BVH) 
  A small family with recurrent vertigo without migraine 
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sodes of vertigo were triggered by exercise and stress, and 
patients showed improvement with acetazolamide. In the 
later stages, when the frequency of vertigo attacks dimin-
ished, the patients developed imbalance and oscillopsia. In 
contrast to the large number of deafness genes, no mutations 
have been identified in BVH with normal hearing. Improv-
ing of phenotyping of patients with recurrent vertigo and 
BVH, excluding ototoxicity is essential to investigate their 
genome. BVH is usually progressive and it is observed after 
longer periods of follow up, usually in subjects over 60 
years-old, making difficult the recruitment of patients within 
a family from more than two generations. Moreover, selec-
tion of sporadic cases with BVH also requires long follow-
up periods to confirm BVH. 
  There has been a single report of linkage analysis in 
families with a dominantly inherited bilateral vestibulopathy 
syndrome associated with migraine and normal hearing [43]. 
The preliminary analysis showed genetic heterogeneity. 
Since the human inner ear transcriptome has been obtained, 
collaborative efforts in identifying and recruiting patients 
with familial vestibulopathy will help identify genes by high 
throughput sequencing methods. 
MENIERE DISEASE 
  Meniere’s disease (MD [MIM 156000]) is defined as an 
inner ear disorder characterized initially by fluctuating low-
frequency sensorineural hearing loss, recurrent vertigo at-
tacks, aural fullness, and tinnitus. Patients experience a high 
frequency of vertigo attacks during the first years which de-
crease over time and develop progressive imbalance and 
severe profound hearing loss [44]. The second ear could be 
affected in around 15-40% of cases. A disturbance of the 
cochlear fluid homeostasis and the endocochlear potential 
has been involved in the development of MD [45], and 
endolymphatic hydrops has been consistently identified as a 
histological feature in temporal bone specimens from pa-
tients with MD. 
  MD is a complex genetic disorder and several features of 
MD suggest a genetic or epigenetic component. The preva-
lence of the disease is more common in European Cauca-
sians than in Asian or African populations. Familial cases 
represent 4-20% of all patients and several MD pedigrees 
have been reported, mostly in Caucasians [46, 47]. 
Familial Meniere’s Disease (FMD) 
  A familial history of MD has been described in 10-19% 
of cases (Table 2). The inheritance of MD has been reported 
to be autosomal dominant with incomplete penetrance esti-
mated around 60% [48-50]. Anticipation for FMD, depend-
ent upon the number of MD patients per generation has been 
described in several families, including both earlier onset 
and tendency to more severe symptoms in successive genera-
tions [51-54]. In addition, several Brazilian families with 
concurrent MD and migraine have also been described [55]. 
  A candidate region for FMD was identified on chromo-
some 12p12.3 from linkage analysis in three large Swedish 
families [56]. This region was analyzed in 15 families with 
several cases segregating FMD in at least two patients. The 
confirmed allelic association defines an haplotype in 12p12.3 
between the markers D12S373 and GT27 [57]. Two genes 
are located in the region: RERG/RAS-like gene (RERGL) 
and PIK3C2G gene; however, none of these genes show any 
alterations in the coding sequences in patients with FMD. In 
contrast, two non-coding SNPs close to exon 29 of 
PIK3C2G, rs12827507 and rs11044211 were strongly asso-
ciated with FMD in Swedish families [57]. 
  Another study in 19 German families with 52 members 
affected by FMD (27% bilateral FMD) found linkage with a 
region on chromosome 5 (LOD score =1.9) and 13/19 fami-
lies showed consistent linkage to the region identified by 
D5S644, which contains 105 known genes [47]. The associa-
tion observed in these families replicates an earlier linkage 
analysis using data from different families. Moreover, these 
families had a prevalence of migraine around 39% and pre-
sented an earlier onset in the third and fourth generation. 
  FMD has also been investigated in Finland in 8 families 
with 17 individuals with definite FMD [58]. The inheritance 
was autosomal dominant and the majority of patients were 
women, a finding also observed in British and German pa-
tients with FMD [47, 49]. A recent study in 16 Finnish fami-
lies did not confirm anticipation, co segregation with mi-
Table 2.  Linkage Association Studies in Familial Ménière’s Disease 
Gene locus   Ethnic   Candidate gene   Anticipation   Replication   Phenotype  
12p12.3   Swedish   PIK3C2G   Y   No   MD, migraine  
14q11-11   UK   None   Y   No   MD, migraine  
DFNA9 - 14p11.2   Belgium, Netherland   COCH   Y   Y  Sensorineural hearing loss and vestibu-
lar dysfunction 
5   German   None   ?   No   MD, migraine.  
Bilateral 27%  
Unknown   Brazilian   None   ?   No   MD and migraine  
Unknown   Finnish   None   No   No   MD  
1q32.1-32.3   Chilean- North Spain   SCLA45A3   ?   No   MD  Genetics of Recurrent Vertigo and Vestibular Disorders  Current Genomics, 2011, Vol. 12, No. 6    447 
graine or linkage to the 12p12.3 region found in Swedish 
FMD, suggesting genetic heterogeneity within FMD [58]. 
  Massive parallel sequencing of the whole exoma in se-
lected cases of FMD is an emerging high-throughput method 
that will facilitate the discovery of new genes by eliminating 
the need for linkage analysis and candidate gene screening 
[59]. 
Sporadic Meniere’s Disease 
  A candidate gene approach, either by case-control studies 
or by the sequencing of selected genes, has been used to 
search genetic markers associated with MD (Table 3). These 
genes include antiquitin [60], aquaporin 2 [61], COCH (co-
agulation factor C homology) [62], potassium channels 
genes (KCNE1 and KCNE3) [63], MHC class II genes [64, 
65], alpha-adducin [66], heat-shock protein 70 [67], PARP-1 
[68], PTPN22 [69], Fc gamma receptors CD32 and CD16a 
[70] and nitric oxide synthases type 1 and 2 [71]. However, 
none of these genes could be replicated in an independent set 
of MD patients [72-74].  
  The HapMap3 Project has defined 10 million single nu-
cleotide polymorphisms (SNPs) throughout the human ge-
nome providing markers for a detailed analysis in any chro-
mosomal region, predicting that an SNP will be in linkage 
disequilibrium to the gene or mutation of interest. The com-
bination of efficient techniques for high throughput genotyp-
ing with dense SNP maps offers a high level of definition for 
genome-wide association studies. 
  SNP-based scans using biallelic polymorphisms are most 
likely to detect common sequence variants associated with 
disease development than candidate gene or familial linkage 
approaches. The effect size of these common variants has 
been small (odds ratio, <2), and a common genetic variant 
will not account for the entire heritability of MD. This ob-
servation leads to investigations of rare variants, copy num-
ber variation, and epigenetic modifications to explain the 
entire heritability of a given disease [75, 76]. Rare structural 
variants are suspected to account for the molecular differ-
ences underlying varied clinical phenotypes and they will be 
associated with FMD. 
  Ultimately, definition of allelic variants for MD will need 
confirmation through experimental modeling demonstrating 
physiologic dysfunction. Discovery of a mechanism of dis-
ease development will advance accuracy of the diagnosis and 
refinement of clinical phenotypes, and provide new targets 
for pharmacologic intervention. Currently, an international 
consortium, named GENOMEN, has been organized to de-
fine the clinical phenotype and to investigate common and 
rare variants in 2000 European Caucasian adults with MD, to 
identify genetic markers for the disease and define its bio-
chemical pathways. 
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